Filing Flows › Comparisons › TSHA vs ALLO
Taysha Gene Therapies vs Allogene Therapeutics: TSHA and ALLO compared
Taysha Gene Therapies is the larger company: $5.5M of revenue in its latest quarter (Q4 2025) against $4.6M for Allogene Therapeutics (Q2 2026).
Where the money goes: TSHA and ALLO
Taysha Gene Therapies (TSHA) · Q4 2025
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
Allogene Therapeutics (ALLO) · Q2 2026
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
| Taysha Gene Therapies (TSHA) | Allogene Therapeutics (ALLO) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $5.5M | $4.6M |
| Revenue growth, Y/Y | +171% | — |
| Operating margin | -516.0% | n/m |
| Net earnings | −$27.9M | −$42.7M |
| Net margin | -507.8% | -919.8% |
| Operating cash flow | −$26.7M | −$32.0M |
Questions
Which is bigger, Taysha Gene Therapies or Allogene Therapeutics?
Taysha Gene Therapies is the larger company: $5.5M of revenue in its latest quarter (Q4 2025) against $4.6M for Allogene Therapeutics (Q2 2026).
More: Taysha Gene Therapies earnings · how Taysha Gene Therapies makes money · Allogene Therapeutics earnings · how Allogene Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 19, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.